JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

Search

Alkermes PLC

Abierto

SectorSanidad

30.16 -3.86

Resumen

Variación precio

24h

Actual

Mínimo

29.88

Máximo

31.32

Métricas clave

By Trading Economics

Ingresos

65M

87M

Ventas

84M

391M

P/B

Media del Sector

14.613

37.461

Margen de beneficios

22.295

Empleados

1,800

EBITDA

99M

113M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+29.09% upside

Dividendos

By Dow Jones

Próximas Ganancias

28 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

802M

5.1B

Apertura anterior

34.02

Cierre anterior

30.16

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

168 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Alkermes PLC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 oct 2025, 22:47 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 oct 2025, 22:13 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 oct 2025, 21:20 UTC

Ganancias

Correction to IBM 3Q Sales Jump Article

22 oct 2025, 20:57 UTC

Ganancias

SAP Posts Higher 3Q Revenue, Operating Profit

22 oct 2025, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 oct 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 oct 2025, 23:41 UTC

Charlas de Mercado

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct 2025, 23:38 UTC

Charlas de Mercado

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct 2025, 23:15 UTC

Ganancias

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 oct 2025, 22:28 UTC

Charlas de Mercado

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 oct 2025, 22:02 UTC

Ganancias

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 oct 2025, 21:59 UTC

Adquisiciones, fusiones, absorciones

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 oct 2025, 21:58 UTC

Adquisiciones, fusiones, absorciones

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 oct 2025, 21:57 UTC

Adquisiciones, fusiones, absorciones

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 oct 2025, 21:56 UTC

Adquisiciones, fusiones, absorciones

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 oct 2025, 21:47 UTC

Adquisiciones, fusiones, absorciones

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 oct 2025, 21:47 UTC

Ganancias

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct 2025, 21:47 UTC

Adquisiciones, fusiones, absorciones

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 oct 2025, 21:46 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 oct 2025, 21:45 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 oct 2025, 21:45 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 oct 2025, 21:28 UTC

Charlas de Mercado
Ganancias

Correction to Alcoa Tariff Market Talk

22 oct 2025, 21:25 UTC

Ganancias

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 oct 2025, 21:17 UTC

Ganancias

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 oct 2025, 21:09 UTC

Charlas de Mercado
Ganancias

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 oct 2025, 21:00 UTC

Charlas de Mercado

ESG Roundup: Market Talk

22 oct 2025, 20:59 UTC

Ganancias

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct 2025, 20:51 UTC

Ganancias

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 oct 2025, 20:44 UTC

Ganancias

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Comparación entre iguales

Cambio de precio

Alkermes PLC previsión

Precio Objetivo

By TipRanks

29.09% repunte

Estimación a 12 Meses

Media 40.6 USD  29.09%

Máximo 47 USD

Mínimo 33 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Alkermes PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

7

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

27.95 / 30.91Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

168 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat